Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Under Article 50 of the Treaty of Lisbon, the United Kingdom will leave the European Union on March 29, 2019 . Presuming that it does (but even if it does not), the U.K. government should continue to lead the charge against antimicrobial resistance (AMR), as it has in the past. Specifically, it is time for the U.K. to join with pharmaceutical companies in piloting a new model of finance for investment in research and development of new antibiotics.Recent developments show that when the right conditions are put in place, there can indeed be a market for developing new antibiotics.Despite this momentum, no government has announced any plans to finance a market-entry reward.I can report that all of the key public-sector stakeholders do want market-entry rewards; and I have even detected a slightly more serious attitude among industry leaders.Assuming that everyone is on board, I would propose that instead of expecting the government to put up the whole $1 billion for a market-entry reward and in order to avoid inviting a revocation of industry-friendly regulations British pharmaceutical companies should come together to contribute 50 percent.
of fiscal policy
as feasible option
Unpredictable Trump’s one-way economy
Does the Group of 20 still
FOLLOW THIS ARTICLE